Nephrology Times
Advertisement
The FDA granted Breakthrough Device Designation to a device to treat chronic systemic inflammation in hemodialysis patients.
Effects of SGLT2 inhibitors on renal outcomes in patients with CKD, heart failure, and type 2 diabetes were examined.
Baxter International has resumed all peritoneal dialysis solutions manufacturing lines at its hurricane-damaged NC facility.
Development of a transplant morbidity gene panel highlights how genetic testing could open the door to personalized care.
Researchers studied outcomes of transplant recipients who received kidneys from toxoplasma-positive versus negative donors.
A study evaluated kidney outcomes of ARNI therapy versus ACEI/ARB for TMA related to malignant hypertension.
A study documented findings on vitamin D and metabolic bone disease in children requiring prolonged CKRT.
The European label for Ozempic will be updated to include risk reduction for events related to kidney disease.
A study examined whether COVID-19 independently affects the subsequent trajectory of kidney function in patients with IgAN.
A study analyzed the fecal microbiome of patients with IgA nephropathy, focusing on their immune response to microbiota.
The NCQA awarded Interwell Health a Population Health Program Accreditation for its Interwell 360 program for those with CKD.
Researchers examined the role of urinary sodium excretion and the progression of immunoglobulin A nephropathy (IgAN).
Obinutuzumab reduced proteinuria in patients with FSGS who were treatment-resistant or on immunosuppressive therapy.
RGLS8429 increases urinary PC1 and PC2 proteins, which may help reduce height-adjusted total kidney volume in ADPKD.
Researchers evaluated the efficacy of sparsentan in a subset of patients with genetic focal segmental glomerulosclerosis.
Len Usvyat spoke with Nephrology Times about the use of artificial intelligence in kidney care.
A study examined whether urate-lowering therapy (ULT) for gout might help delay progression of chronic kidney disease (CKD).
Could pravastatin slow the rate of increase in height-adjusted total kidney volume in adults with ADPKD?
Could the use of potassium binder SZC with dialysate potassium reduce postdialysis heart arrhythmias?
A study examined the efficacy of adding SZC to allow patients with stage 3-4 DKD to maintain treatment with RAASi.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.